Allogene Therapeutics Announces Participation in Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in September. Citi's 2025 Biopharma Back to School SummitWednesday, September 37:30AM PT/10:30AM ET Any available webcasts will be posted to the Company's website at www.allogene.com un ...